source
- Arsenal Biosciences cuts 99 jobs as it pivots to in-vivo CAR-T therapyArsenal Biosciences announced a major restructuring, laying off 99 employees, which represents the majority of its workforce across all teams and locations. The company is ending development of it…
- Alumis' lupus trial misses endpoints, but company eyes phase 3 in IFNGS‑high subgroupAlumis reported that its phase 2b study of the TYK2 inhibitor envudeucitinib failed to meet both the primary and secondary efficacy endpoints in patients with moderate to severe systemic lupus eryt…